Headache Archives - Clinical Advisor

Study Compares Remote Electrical Neuromodulation to Migraine Meds in Adolescents

By

July 12, 2021

Nerivio is a wireless remote electrical neuromodulation device approved for the acute treatment of episodic or chronic migraine in patients 12 years of age and older.

Ortho Dx

OrthoDx: Headache Following Spinal Surgery

June 28, 2021

A 43-year-old man presents 1-week after undergoing an L5-S1 discectomy with complaints of a worsening headache. What is the best treatment option?

Pediatrics Information Center

Nerivio Device Cleared for Migraine in Adolescents

By

Brian Park, PharmD

February 1, 2021

The approval was based on data from an open-label, single-arm study that evaluated the efficacy and safety of Nerivio in patients aged 12 to 17 years with migraine.

Neurology Information Center

FDA Rejects Qtrypta NDA for Acute Treatment of Migraine

By

Brian Park, PharmD

October 29, 2020

Qtrypta delivers zolmitriptan, a selective 5-HT1B/1D receptor agonist, using the Company’s proprietary Adhesive Dermally-Applied Microarray (ADAM) technology that consists of a drug-coated microneedle patch.

Neurology Information Center

Opioid Use Common Among Patients With Migraine

By

Madeline Morr

June 24, 2020

Approximately one-third of patients with migraine reported using opioids to treat their symptoms, a practice that contrasts with current guidelines.

Neurology Information Center

Galcanezumab Linked to Improved Work Productivity in Patients With Migraine

By

Diana Ernst, RPh

June 22, 2020

Galcanezumab was found to significantly improve work productivity and reduce interictal burden in patients with treatment-resistant migraine, according to results from the phase 3 CONQUER study.

Neurology Information Center

Exploring the Link Between Pediatric Migraine & Sleep Disorders

By

Tori Rodriguez, MA, LPC, AHC

June 22, 2020

The bidirectional relationship between migraine and sleep disorders are examined in this article.

Neurology Information Center

Positive Outcomes Reported With Novel Intranasal DHE for Migraine

By

Brian Park, PharmD

June 19, 2020

Positive results were announced from the phase 3 STOP-301 study evaluating INP104 (intranasal dihydroergotamine mesylate; Impel NeuroPharma) for the treatment of acute migraine in adults.